Vascepa Decision; Approve Now or Wait for CV Outcomes?
By Catherine Shaffer
Monday, October 14, 2013
The FDA released briefing documents ahead of Wednesday’s Endocrinologic and Metabolic Drugs Advisory Committee meeting to consider approval of Amarin Corp.’s Vascepa as an add-on to statin therapy for patients with mixed dyslipidemia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.